

# CURRICULUM VITAE

**Yan Lin, PhD**

BUSINESS ADDRESS: Sterling Plaza  
201 North Craig Street  
Suite 350  
Pittsburgh, PA 15213

Phone: (412)383-1311  
Fax: (412)383-1387  
E-mail: liny@nrgoncology.org

## EDUCATION AND TRAINING

### Graduate

2003-2007	University of Pittsburgh, Pittsburgh, PA	PhD, 2007	Biostatistics
2001-2003	University of Pittsburgh, Pittsburgh, PA	MS, 2003	Biostatistics
1994-2001	University of Michigan, Ann Arbor, MI	PhD, 2001	Biology

### Undergraduate

1990 -1994	Beijing Normal University Beijing, China	BS, 1994	Biology
------------	---	----------	---------

## APPOINTMENTS AND POSITIONS

### Academic

2/2016 - Present	Research Associate Professor (Primary)	Department of Biostatistics, GSPH, University of Pittsburgh, Pittsburgh PA
7/2009 – 1/2016	Research Assistant Professor (Primary)	Department of Biostatistics, GSPH, University of Pittsburgh, Pittsburgh PA

6/2007-6/2009	Assistant Professor (Primary)	Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh PA
6/2007-6/2009	Assistant Professor (Secondary)	Department of Biostatistics, GSPH, University of Pittsburgh, Pittsburgh PA
6/2007-6/2009	Assistant Professor (Secondary)	Clinical and Translational Science Institute (CTSI), School of Medicine, University of Pittsburgh, Pittsburgh PA
<b>Non-Academic</b>		
10/2019-present	Senior Biostatistician	NRG Oncology, Statistics and Data Management Center (formerly NSABP) Pittsburgh, PA
7/2009-9/2019	Senior Biostatistician	UPMC Hillman Cancer Center (formerly UPCI), University of Pittsburgh, Pittsburgh, PA
6/2003-12/2004	Biostatistician	University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA

## MEMBERSHIP IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

2003 - Present	Member, American Statistical Association (ASA)
2003 - Present	Member, The Eastern North American Region of the International Biometric Society (ENAR)
2003 - Present	Member, American Society of Human Genetics (ASHG)
2017 - 2018	American Association of Cancer Research (AACR)

## HONORS AND AWARDS

1997	Newcomb Fellowship University of Michigan
2003	Outstanding Student Award Department of Biostatistics, University of Pittsburgh
2007	Student Distinguished Paper Award International Biometric Society, Eastern North American Region (ENAR)

## PROFESSIONAL ACTIVITIES

### 1. Teaching and Research Activities

#### a. Courses Taught

<b>Years Taught</b>	<b>Course Number: Title</b>	<b>Role in course Primary/Coordinator</b>
2007-2008	CLRES2022, Logistic Regression	Co-instructor
2007-2008	CLRES2071, Research Design and Development Seminar Part I	Statistical Consultant
2008-2009	CLRES2023, Survival Analysis	Co-instructor
2011-2015	BIOST - 2055 - 14860, INTROD GNOMC ANAL 1: APPLCS	Co-instructor
2011-2015	BIOST - 2055 - 14860, INTROD GNOMC ANAL 1: APPLCS	Co-instructor
2010-2017	MED5715, Neoplasia & Neoplastic Disease	Guest Lecturer

#### b. Other Teaching (lectures, tutorials and continuing education courses)

<b>Date(s)</b>	<b>Type of Teaching</b>	<b>Title</b>
2008	Unified Fellow Workshop	Introduction to Statistics and Study Design

### c. Major Advisor for Graduate Student Essays, Theses, and Dissertations

<b>Name of Student</b>	<b>Degree Awarded, Year</b>	<b>Type of Document and Title</b>	<b>Notes</b>
Fei Ding	2013	MS Thesis: A comparative study of different strategies of batch effect removal in array data: a case study of three datasets	Committee Chair
Ying Qiang	2015	MS Thesis: Searching for the prognostic factors for later stage melanoma patients treated with HDI using immunochip data	Committee Chair
Hui-Min Lin	2015	PhD Dissertation: Behavior of statistics for genetic association in a genome-wide scan context	Co-chair with Dr. Feingold
Surui Hou	2018	MS Thesis: Integrated clustering analysis of UPCI 08-144 correlative studies.	Committee Chair

### d. Service on Master or Doctoral Committees

<b>Dates Served</b>	<b>Name of Student</b>	<b>Degree Awarded</b>	<b>Title of Dissertation/Essay</b>
2009	Sun-Hee Oh	PhD	Effects of missing value imputation on down-stream analyses in microarray data
2010	Soo Yeon Cheong	PhD	Statistical Methods for Genotyping Assay Data
2011	Xingbin Wang	PhD	Genomic meta-analysis combining microarray studies with confounded clinical variables: application to depression analysis
2011	Chang Sook Hong	MS	Studies of Association of Environmental Risk Factors in Down Syndrome
2012	Wenzhu Bi	PhD	Enhancements of Sparse Clustering with Resampling and Considerations on Tuning Parameter
2013	Nathan Pugh	PhD	Outlier detection methods applied to MRI data.
2013	Umut Ozbek	PhD	Statistical Methods for Recovering GWAS Data
2013	Ferdouse Begum	PhD	GWAS Meta-Analysis: Methodology and Application to Meiotic Recombination

<b>Dates Served</b>	<b>Name of Student</b>	<b>Degree Awarded</b>	<b>Title of Dissertation/Essay</b>
2013	Dilrukshia Singhabahu	PhD	Robust Partial Least Squares Regression and Outlier Detection using Repeated Minimum Covariance Determinant Method and a Resampling Method
2014	Serena Liao	PhD	Missing value imputation in high-dimensional phenomic data
2014	Ming Geng	PhD	Marginal structural COX proportional hazards model for data with competing risk and measurement
2015	Beth Zamboni	PhD	TWISTed survival: identifying surrogate endpoints for mortality using QTWIST and conditional disease-free survival.
2017	Abraham Apfei	PhD	Stability Analysis of Sparse K-means
2017	Yi Yao	MS	Comparison of novel phase I clinical trial designs based on toxicity probability intervals.
2017	Xinmei Zhu	MS	Age-period-cohort effects on the development of cognitive impairment among the elderly.
2018	Winston Wing Hong Eng	MS	Exploring the genetic characteristics underlying a multidimensional latent chemotherapy symptom burden

## 2. Current Research Support

<b>Years Inclusive</b>	<b>Grant and/or Contract Number and Title</b>	<b>Source</b>	<b>Annual Direct Costs</b>	<b>% Effort</b>
10/1/2019 – 12/31/2025	A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo	NASBP Foundation	\$276,548	50%

<b>Years Inclusive</b>	<b>Grant and/or Contract Number and Title</b>	<b>Source</b>	<b>Annual Direct Costs</b>	<b>% Effort</b>
10/1/2019 – 2/20/2025	2U10CA180822 (Dignam, J.)	NCI	\$5,141,357	40%
7/1/19-6/30/24	R01 CA239716-01A1 (Lu, B): Study of Interleukin 33 as new immunotherapy of lung cancer	NCI	\$8,425	5%
6/15/17-6/30/19	Abatacept in ILD Clinical Trial – ATTACK MY ILD Study	Industry	\$7,537	5%

## PUBLICATIONS

### Refereed Articles

1. Appleman, L. J., Beumer, J. H., Jiang, Y., **Lin, Y.**, Ding, F., Puhalla, S., . . . Ramalingam, S. S. (2019). Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.. *Cancer Chemother Pharmacol.* doi:10.1007/s00280-019-03960-w
2. Faden, D. L., Ding, F., **Lin, Y.**, Zhai, S., Kuo, F., Chan, T. A., . . . Ferris, R. L. (2019). APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. *ORAL ONCOLOGY*, 96, 140-147. doi:10.1016/j.oraloncology.2019.07.020
3. Butterfield LH, Vujanovic L, Santos PM, Maurer DM, Gambotto A, Lohr J, Li C, Waldman J, Chandran U, **Lin Y**, Lin H, Tawbi HA, Tarhini AA, Kirkwood JM. (2019) Multiple antigen-engineered DC vaccines with or without IFN $\alpha$  to promote antitumor immunity in melanoma. *J Immunother Cancer*. 2019 Apr 24;7(1):113. doi: 10.1186/s40425-019-0552-x.PMID: 31014399
4. Shurin, G. V., Kruglov, O., Ding, F., **Lin, Y.**, Hao, X., Keskinov, A. A., . . . Bunimovich, Y. L. (2019). Melanoma-induced reprogramming of Schwann cell signaling aids tumor growth.. *Cancer Res.* doi:10.1158/0008-5472.CAN-18-3872
5. Vujanovic L, Chuckran C, **Lin Y**, Ding F, Sander CA, Santos PM, Lohr J, Mashadi-Hosseini A, Warren S, White A, Huang A, Kirkwood JM, Butterfield LH. CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon- $\alpha$ . *Front Immunol*. 2019 Jan 29;10:14. PMID: 30761123 PMCID: PMC6361792
6. Tarhini A, **Lin Y**, Lin H, Rahman Z, Vallabhaneni P, Mendiratta P, Pingpank JF, Holtzman MP, Yusko EC, Rytlewski JA, Rao UNM, Ferris RL, Kirkwood JM: Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN- $\alpha$ 2b in locally/regionally advanced melanoma:

safety, efficacy and impact on T-cell repertoire. *J Immunother Cancer*. 2018 Oct 23;6(1):112. PMID: 30352626 PMCID: PMC6199801

7. Özbek U, Lin HM, **Lin Y**, Weeks DE, Chen W, Shaffer JR, Purcell SM, Feingold E Statistics for X-chromosome associations. *Genet Epidemiol*. 2018 Sept 42(6): 539-550 doi: 10.1002/gepi. 22132
8. Kansy BA, Shayan G, Jie HB, Gibson SP, Lei YL, Brandau S, Lang S, Schmitt NC, Ding F, **Lin Y**, Ferris RL. T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response. *Oncoimmunology*. 2018 Aug 24;7(11): e1494112 PMID: 30377562 PMCID: PMC620504
9. Retseck J, Nasr A, **Lin Y**, Lin H, Mendiratta P, Butterfield LH, Tarhini AA. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. *J Transl Med*. 2018 Jul 4;16(1):184. PMID: 29973204 PMCID: PMC6033230
10. Yoneyama T, Gorry M, Sobo-Vujanovic A, **Lin Y**, Vujanovic L, Gaither-Davis A, Moss ML, Miller MA, Griffith LG, Lauffenburger DA, Stabile LP, Herman J, Vujanovic NL. ADAM10 Sheddase Activity is a Potential Lung-Cancer Biomarker. *J Cancer*. 2018 Jun 23;9(14):2559-2570. PMID: 30026855 PMCID: PMC6036891
11. Tahata S, Singh SV, **Lin Y**, Hahm ER, Beumer JH, Christner SM, Rao UN, Sander C, Tarhini AA, Tawbi H, Ferris LK, Wilson M, Rose A, Dietz CM, Hughes EK, Fahey JW, Leachman SA, Cassidy PB, Butterfield LH, Zarour HM, Kirkwood JM. Evaluation of biodistribution of sulforaphane after administration of oral broccoli sprout extract in melanoma patients with multiple atypical nevi. *Cancer Prev Res (Phila)*. 2018 Apr 24. pii: canprevres.0268.2017. doi: 10.1158/1940-6207.CAPR-17-0268 [Epub ahead of print] PMID: 29691233 PMCID: PMC6030491
12. Tarhini AA, Floros T, Lin HM, **Lin Y**, Rahman Z, Ashraf M, Vallabhaneni P, Sander C, Rao UNM, Panelli M, LaFramboise WF, Kirkwood JM. A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma. *Melanoma Res*. 2017 Oct;27(5):429-438. PMID: 28825947 PMCID: PMC5657445
13. Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, **Lin Y**, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH. Phase I study of veliparib in combination with gemcitabine. *Cancer Chemother Pharmacol*. 2017 Sep;80(3):631-643. PMID: 28770300 PMCID: PMC5734661
14. Tarhini AA, Moschos SJ, **Lin Y**, Lin HM, Sander C, Yin Y, Venhaus R, Gajewski TF, Kirkwood JM. Safety and efficacy of the antiganglioside GD3 antibody ecomeximab (KW2871) combined with high-dose interferon- $\alpha$ 2b in patients with metastatic melanoma. *Melanoma Res*. 2017 Aug;27(4):342-350. PMID: 28489678 PMCID: PMC Journal – In Process

15. Tarhini AA, **Lin Y**, Lin HM, Vallabhaneni P, Sander C, LaFramboise W, Hamieh L. Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit. *Oncoimmunology*. 2016 Sep 19;6(2):e1231291. PMID: 28344862 PMCID: PMC5353928
16. Yoneyama, T., Gorry, M., Miller, M. A., Gaither-Davis, A., **Lin, Y.**, Moss, M. L., . . . Vujanovic, N. L. (2017). Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates. *JOURNAL OF CANCER*, 8(19), 3916-3932. doi:10.7150/jca.20779 PMID: 29187866 PMCID: PMC5705993
17. Najjar YG, Ding F, **Lin Y**, VanderWeele R, Butterfield LH, Tarhini AA. Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab. *J Transl Med*. 2017 Feb 21;15(1):39. PMID: 28222797 PMCID: PMC5319167.
18. Ferris LK, Saul MI, **Lin Y**, Ding F, Weinstock MA, Geller AC, Yuan JM, Neuren E, Maddukuri S, Solano FX, Kirkwood JM. A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes. *JAMA Oncol*. 2017 Aug 1;3(8):1112-1115. PMID: 28241191 PMCID: PMC5552417
19. Gyanchandani R, **Lin Y**, Lin HM, Cooper K, Normolle DP, Brufsky A, Fastuca M, Crosson W, Oesterreich S, Davidson NE, Bhargava R, Dabbs DJ, Lee AE. Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer. *Clin Cancer Res*. 2016 Nov 1;22(21):5362-5369. PMID: 27185370 PMCID: PMC5093028
20. Retseck J, VanderWeele R, Lin HM, **Lin Y**, Butterfield LH, Tarhini AA. Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. *J Immunother Cancer*. 2016 Jun 21;4:38. PMID: 27330811 PMCID: PMC4915044
21. Kansy, B. A., Lin, Y., Ding, F., Gibson, S., Jie, H. -B., & Ferris, R. L. (2015). Anti-EGFR mAb cetuximab therapy increases T cell receptor (TCR) diversity in the peripheral blood and focuses TCR richness in the tumor microenvironment. *Journal for ImmunoTherapy of Cancer*, 3(Suppl 2), P73. doi:10.1186/2051-1426-3-S2-P73 PMCID: PMC4646103
22. Sobo-Vujanovic A, Vujanovic L, DeLeo AB, Concha-Benavente F, Ferris RL, **Lin Y**, Vujanovic NL. Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice. *Cancer Immunol Res*. 2016 May;4(5)441-51. PMID: 26896171 PMCID: PMC4873325.
23. Beumer JH, Ding F, Tawbi H, **Lin Y**, Viluh D, Chatterjee I, Rinker M, Chow SL, Ivy SP. Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation



Program-Sponsored Single-Agent Phase I Studies. *J Clin Oncol*. 2016 Jan 10;34(2):110-6. PMID: 26392101 PMCID: PMC4980565

24. Ross K, Gillespie-Twardy AL, , Agha M, Raptis A, Hou JZ, Farah R, Redner RL, Im A, Duggal S, Ding F, **Lin Y**, Boyiadzis, M. Intensive chemotherapy in patients aged 70 years or Older Newly Diagnosed With Acute Myeloid Leukemia. *Oncol Res*. 2015;22(2):85-92. PMID: 25706395 PMCID: PMC Journal –In Process
25. Tarhini, A. A., Zahoor, H., **Lin, Y.**, Malhotra, U., Sander, C., Butterfield, L. H., & Kirkwood, J. M. (2015). Baseline circulating IL-17 predicts toxicity while TGF-beta 1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. *JOURNAL FOR IMMUNOTHERAPY OF CANCER*, 3. doi:10.1186/s40425-015-0081-1
26. Davar D, **Lin Y**, Kirkwood JM. Unfolding the mutational landscape of human melanoma. *J Invest Dermatol*. 2015 Mar;135(3):659-62. PMID: 25666674 PMCID: PMC4466551
27. Weissfeld JL, **Lin Y**, Lin HM, Kurland BF, Wilson DO, Fuhrman CR, Pennathur A, Romkes M, Nukui T, Yuan JM, Siegfried JM, Diergaarde B. Lung cancer risk prediction using common SNPs located in GWAS-identified susceptibility regions. *J Thorac Oncol*. 2015 Nov;10(11):1538-45. PMID: 26352532 PMCID: PMC4636453
28. Tarhini AA, **Lin Y**, Zahoor H, Shuai Y, Butterfield LH, Ringquist S, Gogas H, Sander C, Lee S, Agarwala SS, Kirwood. JM. Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon- $\alpha$  but Not Observation in Intermediate Risk Melanoma Patients. *PLoS One*. 2015 Jul 20;10(7):e0132745 PMID: 26192408 PMCID: PMC4508028
29. Siegfried JM, **Lin Y**, Diergaarde B, Lin HM, Dacic S, Pennathur A, Weissfeld JL, Romkes M, Nukui T, Stabile LP. Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome. *Neoplasia*. 2015 Nov;17(11):817-25. PMID: 26678909 PMCID: PMC4681883
30. Tawbi H, Christner SM, **Lin Y**, Johnson M, Mowrey ET, Cherrin C, Chu E, Lee JJ, Puhalla S, Stoller R, Appleman LR, Miller BM, Beumer JH. Calcium Carbonate does not Affect Imatinib Pharmacokinetics in Healthy Volunteers. *Cancer Chemother Pharmacol*. 2014 Jan;73(1):207-11. PMID: 24170263 PMCID:3880632
31. Tarhini AA, **Lin Y**, Yeku O, LaFramboise WA, Ashraf M, Sander C, Lee S, Kirkwood JM. A Four- Marker Signature of TNF-RII, TGF- $\alpha$ , TIMP-1 and CRP is Prognostic of Worse Survival in High-Risk Surgically Resected Melanoma. *J Transl Med*. 2014 Jan 23;12:19. PMID: 24457057 PMCID: 3909384
32. Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, Rao UN, Kirkwood JM. Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving

- Neoadjuvant Ipilimumab. PLoS One. 2014 Feb 3;9(2):e87705. PMID: 24498358 PMCID: 3912016
33. Tawbi, H. A., Tran, A. L., Christner, S. M., Lin, Y., Johnson, M., Mowrey, E., . . . Beumer, J. H. (2013). Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. *CANCER CHEMOTHERAPY AND PHARMACOLOGY*, 72(5), 1143-1147. doi:10.1007/s00280-013-2283-x PMID:24036846 PMCID:PMC3818249
34. Lowe DB, Bose A, Taylor JL, Tawbi HA, **Lin Y**, Kirkwood JM, Storkus WJ. Dasatinib Promotes an Expanded and Therapeutically-Superior T Cell Repertoire in Response to Vaccination Against Melanoma. *OncoImmunology*. 2014 Jan 1;3(1):e27589. PMID: 24734217 PMCID: 3984268
35. Geskin LJ, Akilov OE, **Lin Y**, Lokshin AE. Distinct Age-Matched Serum Biomarkers Profiles in Patients with Cutaneous T-Cell Lymphoma. *Exp Dermatol*. 2014 Aug;23(8):598-600. PMID: 24862743 PMCID: 4125529
36. Liao SG, **Lin Y**, Kang DD, Chandra D, Bon J, Kaminski N, Sciurba FC, Tseng GC. Missing value imputation in high-dimensional phenomic data: imputable or not, and how? *BMC Bioinformatics*. 2014 Nov 5;15(1):346. PMID: 25371041 PMCID: 4228077
37. Ding Y, Tang S, Liao SG, Jia J, Oesterreich S, **Lin Y**, Tseng GC. Bias correction for selecting the minimal-error classifier from many machine learning models. *Bioinformatics*. 2014 Nov 15;30(22):3152-8. PMID: 25086004 PMCID: 4221122
38. Hamilton R, Krauze M, Romkes M, Omolo B, Konstantinopoulos P, Reinhart T, Harasymczuk M, Wang Y, **Lin Y**, Ferrone S, Whiteside T, Bortoluzzi S, Werley J, Nukui T, Fallert-Junecko B, Kondziolka D, Ibrahim J, Becker D, Kirkwood J, Moschos S. Pathologic and Gene Expression Features of Metastatic Melanomas to the Brain. *Cancer*. 2013 May 21. PMID: 23695963 PMCID: 3901051
39. Tawbi HA, Beumer JH, Tarhini AA, Moschos S, Buch SC, Egorin MJ, **Lin Y**, Christner S, Kirkwood JM. Safety and Efficacy of Decitabine in Combination with Temozolomide in Metastatic Melanoma: A Phase I/II Study and Pharmacokinetic Analysis. *Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO*. 2013 Apr;24(4):1112-9. PMID: 23172636. PMCID: 3603441.
40. Suryawanshi S, Vlad AM, Lin HM, Mantia-Smaldone G, Laskey R, Lee M, **Lin Y**, Donnellan N, Klein-Patel M, Lee T, Mansuria S, Elishaev E, Budiu R, Edwards RP, Huang X. Plasma MicroRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associated Ovarian Cancer. *Clinical Cancer Research : An Official Journal of the American Association for Cancer Research*. 2013 Mar 1;19(5):1213-24. PMID: 23362326. PMCID: 3596045.

41. Wang XB, **Lin Y**, Song C, Sibille E and Tseng GC. Detecting Disease-Associated Genes with Confounding Variable Adjustment and the Impact on Genomic Meta-Analysis: with Application to Major Depressive Disorder. *BMC Bioinformatics* 2012; 13 (1): 52. PMID: 22458711 PMCID: 3342232
42. Chang G, Chen L, Lin HM, **Lin Y**, Maranchie JK. Nox4 Inhibition Enhances the Cytotoxicity of Cisplatin in Human Renal Cancer Cells. *Journal of Experimental Therapeutics & Oncology*. 2012; 10 (1):9-18. PMID: 22946340 PMCID: N/A
43. Zhang Q, Kanterewicz B, Buch S, Parise R, Beumer J, **Lin Y**, Hershberger PA. CYP24 Inhibition Preserves 1,25-Dihydroxyvitamin D3 Anti-Proliferative Signaling in Lung Cancer Cells. *Mol Cell Endocrinol*: 2012; 355 (1):153-161 PMID: 22386975 PMCID: 3312998.
44. Wang X, Kang DD, Shen K, Song C, Lu S, Chang LC, Liao SG, Huo Z, Tang S, Kaminski N, Sibille E, **Lin Y**, Li J, Tseng GC. An R Package Suite for Microarray Meta-Analysis in Quality Control, Differentially Expressed Gene Analysis and Pathway Enrichment Detection. *Bioinformatics* 2012 Oct 1;28(19):2534-6. PMID: 22863766 PMCID: 3463115
45. Cetin S, Tobey AB, Sandulache VC, Yang T, Barsic M, **Lin Y**, Dohar JE, Hebda PA. Cyclooxygenase-2 Inhibition for the Prevention of Subglottic Stenosis. *Archives of Otolaryngology--Head & Neck Surgery*. 2012 Oct 1; 138 (10):962-8. PMID: 23069827 PMCID: 4126655
46. Ho J, Barbi de Moura M, **Lin Y**, Vincent G, Thorne S, Duncan LM, Lin HM, Kirkwood JM, Becker D, van Houten B, Moschos S. Importance of Glycolysis and Oxidative Phosphorylation in Advanced Melanoma. *Molecular Cancer*. 2012 Oct 9; 11 (1):76. PMID: 23043612 PMCID: 3537610
47. McLaughlin B, Im A, Raptis A, Agha M, Hou JZ, Redner R, Duggal S, **Lin Y**, Smith C, Boyiadzis M. Fludarabine and Cytarabine in Patients with Relapsed Acute Myeloid Leukemia Refractory to Initial Salvage Therapy. *International Journal of Hematology*. 2012 Dec; 96 (6):743-7. PMID: 23132594 PMCID: N/A
48. Tarhini AA, Leng S, Moschos S, **Yin Y**, Sander C, Lin Y, Gooding W, Kirkwood JM. Safety and Immunogenicity of Vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and Tyrosinase (368-376, 370D) in-Adjuvant with PF-3512676 and GM-CSF in Metastatic Melanoma. *J Immunother* 2012; 35(4): 359-366. PMID: 22495394 PMCID: 3483091
49. Linkov F, Maxwell GL, Felix AS, **Lin Y**, Lenzner D, Bovbjerg DH, Lokshin A, Hennon M, Jakicic JM, Goodpaster BH, DeLany JP. Longitudinal evaluation of cancer-associated biomarkers before and after weight loss in RENEW study participants: implications for cancer risk reduction. *Gynecol Oncol*. 2012 Apr;125(1):114-9. PMID: 22198242 PMCID: PMC4387771
50. Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF Jr, Wetzel LH,,

Martin D, Lockart ME, Bennett WM, Moxey-Mims M, Abebe KZ, **Lin Y**, Bost JE, for the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. *Clin J Am Soc Nephrol*. 2011; 6(3):640-647. PMID: 21088290 PMCID: PMC3082424

51. Hannon TS, Lee S, Chakravorty S, **Lin Y**, Arslanian SA. Sleep-disordered breathing in obese adolescents is associated with visceral adiposity and markers of insulin resistance. *Int J Pediatr Obes*. 2011 Apr;6(2): 157-60. PMID: 20545482 PMCID: 3428196
52. Manrique AM, Arroryo M, **Lin Y**, El Khoudary SR, Colvin E, Lichtenstein S, Chrysostomou C, Orr R, Jooste E, Davis P, Wearden P, Morell V, Munoz R. Magnesium supplementation during cardiopulmonary bypass to prevent junctional ectopic tachycardia after pediatric cardiac surgery: A randomized controlled study. *J Thorac Cardiovasc Surg* 2010 Jan; 139 (1) :162-169. PMID 19819469 PMCID: N/A
53. Goyal RK, **Lin Y**, Livote E, Fairfull L, Yanik G, Ferrell RE, Schultz K, Zorich GP, Atlas M. TNF- $\alpha$  and TNF receptor super family member 1B polymorphisms predict risk of acute AvHG following matched unrelated donor BMT in children: a pediatric blood and marrow transplant consortium study. *Biol Blood Marrow Transplantat*. 2010 Jul; 16 (7): 927-936. PMID 20100586 PMCID: N/A
54. Jayaram A, Zeevi A, Bentlejewski C, **Lin Y**, Michaels MG. Immune response of young children using ATP based Cylex Assay: a brief report. *Pediatric Transplant*. 2010 Aug; 14 (5): 664-666. PMID 20345614 PMCID: N/A
55. Shaikh N, Kearney DH, Colborn DK, Balentine T, Feng W, **Lin Y**, Hoberman A. How do parents of preverbal children with acute otitis media determine how much ear pain their child is having? *The Journal of Pain*. 2010; 11(12):1291-1294. PMID 20466597 PMCID: 3072575
56. Ramaligham SS, Kummar S, Sarantopoulos J, Shibata S, Lorusso P, Harvey RD, Yerk M, **Lin Y**, Beumer JH, Ivy SP, Belani CP, Egorin M. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI # 8057). *J Clin Oncol* . 2010 Dec; 28 (29). PMID: 20837947 PMCID: 2988640
57. O'Malley KJ, Dhir R, Nelson JB, Bost J, **Lin Y**, Wang Z. The expression of androgen-responsive genes is Up-Regulated in the epithelia of benign prostatic hyperplasia. *Prostate*. 2009 Dec 1; 69 (16):1716-1723. PMID 19676094 PMCID: 2804845
58. Jayaram A, Zeevi A, Goyal R, Bentlejewski C, **Lin Y**, Michaels MG. Cord blood lymphocytes show higher ATP production compared to peripheral blood lymphocytes from children and adults. *JNPM*. 2009, 2 (4)

59. Hannon T, Bacha F, **Lin Y**, Arslanian S. Hyperinsulinemia in African American adolescents compared with their American white peers despite similar insulin sensitivity: a reflection of up-regulated  $\beta$ -cell function? *Diabetes Care* 2008 Jul;31(7):1445-1447. PMID: 18417751 PMCID: 2453672
60. **Lin Y**, Tseng G, Cheong SY, Bean LJ, Sherman SL, Feingold E. Smarter clustering methods for high-throughput SNP genotype calling. *Bioinformatics* 2008 Dec 1;24(23):2665-2671. PMID: 18826959 PMCID: 2732271
61. Simon M, Lee MM, **Lin Y**, Gish L, Schiefelbein J. Distinct and overlapping roles of single-repeat MYB genes in root epidermal patterning. *Developmental Biology* 2007 Nov 15; 311(2): 566-578. PMID: 17931617
62. Axtell AE, Kelley JL, Fader AN, Gupta D, Schwartz B, Comerci JT, **Lin Y**, Weiland S, Gallion HH, Kanbour-Shakir A. Percent surface area involvement is a predictor of lymph node metastasis in endometrial cancer. *Gynecol Oncol.* 2007 Dec;107(3):482-6. Epub 2007 Sep 11. PMID 17850853
63. Maheshwari V, Tsung A, **Lin Y**, Zeh HJ, Finkelstein SD, Bartlett DL. Analysis of loss of heterozygosity for tumor-suppressor genes can accurately classify and predict the clinical behavior of mucinous tumors arising from the appendix. *Annals of Surgical Oncology* 2006;13:1610-1616. PMID: 17009159
64. Gerszten K, Gooding WE, **Lin Y**, Heron DE, Faul C. A single institutional experience with definitive radiotherapy for cervical cancer using both high- and low-dose-rate brachytherapy. *Gynecologic Oncology* 2006;102(3):500-507. PMID: 16503346
65. Esposito NN, Mohan D, Brufsky A, **Lin Y**, Kapali M, Dabbs DJ. Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. *Archives of Pathology and Laboratory Medicine* 2006;130(10):1516-1521. PMID: 17090194
66. Ahuja SP, Greenspan SL, **Lin Y**, Bowen A, Bartels BS, Goyal RK. Heel ultrasound: a non-invasive method to screen for low bone mass in children with leukemia. *Journal of Pediatric Blood and Cancer* 2006; 28:427-432. PMID: 16825988
67. Kelavkar U, **Lin Y**, Landsittel D, Chandran U, Dhir R. The yin and yang of 15-lipoxygenase-1 and delta-desaturases: dietary omega-6 linoleic acid metabolic pathway in prostate. *Journal of Carcinogenesis* 2006; 5:9. PMCID: 1440856
68. Mohamed MK, Ramalingam S, **Lin Y**, Gooding W, Belani CP. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. *Annals of Oncology* 2005;16:780-785.
69. Zhang X, Chen Z, Choe MS, **Lin Y**, Sun SY, Wieand HS, Shin HJ, Chen A, Khuri FR, Shin DM. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. *Clinical Cancer Research* 2005;11:6261-6269.

70. **Lin Y**, Feingold E, Reynolds P. An empirical Bayesian method for differential expression studies using one-channel microarray data. *Statistical Applications in Genetics and Molecular Biology* 2003;2(1):article 8
71. **Lin Y**, Schiefelbein J. Embryonic control of epidermal cell patterning in the root and hypocotyl of *Arabidopsis*. *Development* 2001;128:3697-3705.
72. Hung CY, **Lin Y**, Zhang M, Pollock S, Marks MD, Schiefelbein J. A common position-dependent mechanism controls cell-type patterning and *GLABRA2* regulation in the root and hypocotyl epidermis of *Arabidopsis*. *Plant Physiology* 1998;117:73-84.

## 2. Presentations

1. Lin Y, Feingold E, Reynolds PR. An empirical Bayesian method for differential expression studies using one-channel microarray data. Presented at: Joint Statistical Meeting (JSM); 2003 Aug 3-7; San Francisco, California.
2. Statistical Issues in Family-Based Genetic Association Studies with Application to Congenital Heart Defects in Down Syndrome. 2006 Sep; Presented at: Data Center, Center for Research on Health Care, University of Pittsburgh.
3. Lin Y, Tseng GC, cheong SY, Feingold E. Smarter Clustering Methods for High-throughput SNP Genotype Calling. Presented at: ENAR; 2007 Mar 11-14; Atlanta, Georgia.
4. Lin Y. Design and Analysis of Clinical Genetic Association Study. Presented at: Health Services Research Seminar Series; 2007 Dec; Center for Research on Health Care, University of Pittsburgh. (Invited)
5. Lin Y, Tseng GC, Cheong SY, Bean LJ, Sherman SL, Feingold E. Smarter Clustering Methods for High-throughput SNP Genotype Calling. 2009 Mar; Presented at: UPCI Biostatistic Facility, University of Pittsburgh. (Invited)
6. Lin Y. Quality Issues with Multi-plex Protein Array Data. Presented at: Inter-SPORE Symposium at JSM; 2010 Aug 2; Vancouver, British Columbia, Canada.
7. Lin Y. A Brief Overview of Microarray Data Analysis. 2012 May; Presented at: Head and Neck Cancer Signaling Group, Department of Otolaryngology, University of Pittsburgh. (Invited)
8. Lin Y, Butterfield LH, LaFramboise W, Potter D, Lin H, sander c, Kirkwood JM, Tarhini A. Comparison of SearchLight and Luminex multiplex assays: A case study of 27 cytokines in 156 melanoma blood serum samples. Presented at: Markers in Cancer 2012; 2012 Oct 11-13; Hollywood, Florida.
9. Lin Y, Cheong S, Feingold Eleanor. Genotype Calling in Trisomic Samples. Presented at: Joint Statistical Meetings (JSM) 2014; 2014 Aug 2-7; Boston, MA.

10. Lin Y. Statistical design of phase I oncology trials. 2018 March. Presented at: BDMC, Department of Critical Care, University of Pittsburgh. (Invited)

# SERVICE

## 1. Service to School and University

<b>Years</b>	<b>Committee</b>	<b>Position</b>
2007	The Committee of the Pediatric Clinical and Translational Research Center (PCTRC, standing)	Statistical Reviewer (appointed)
2009-2019	The UPCI protocol review committee (PRC, standing)	Statistical Reviewer (appointed)
2011 - 2019	Clinical pharmacology analytical facility advisory committee (standing)	Committee member (appointed)
2011 - 2019	UPCI Melanoma-Sacoma Data and Safety Monitoring Committee (standing)	Committee member (appointed)
2011 - 2019	UPCI Phase I Group Data and Safety Monitoring Committee (standing)	Committee member (appointed)
2012-2019	Cancer Informatics Service Advisory Committee (standing)	Committee member (appointed)

## 2. Service to Field of Scholarship

### a. Editorial Boards, Editorships

<b>Date</b>	<b>Position</b>	<b>Organization</b>
6/2014 - Present	Statistical Editor	Journal of National Cancer Institute
2010-2015	Statistical Consultant	Wound Repair and Regeneration

### b. Manuscript and Other Document/Publication Review

<b>Dates</b>	<b>Journal Title</b>
2003 - 2009	Statistical Applications in Genetics and Molecular Biology
2003 - Present	Journal of Clinical Oncology
2008	International Journal of Radiation Oncology
2008, 2009	Bioinformatics



<b>Dates</b>	<b>Journal Title</b>
2009	Stroke
2009	Book chapter reviewer, The Springer (2009). “Logistic Regression: A Self-Learning Text, Third Edition” by David Kleinbaum and Mitchel Klein: Chapters 8-10.
2009-present	Wound Repair and Regeneration
2013	Nature Communications
2013	PLOS ONE
2014-present	Journal of National Cancer Institute
2017	British Journal of Dermatology

### **c. Study Sections, Review Panels, and Advisory Boards**

<b>Date</b>	<b>Position</b>	<b>Organization and Nature of Activity</b>
2009	Reviewer	NIH Challenge grants, Stage 1
2011-2015	Reviewer	Small Grants for Cancer Epidemiology (R03), NCI
2012	Reviewer	Research Answers to NCI Provocative Questions, NCI
2018	Reviewer	NCI special emphasis panel, ZCA1 RPRB-N(M)2 (P01)